Montana Opens Doors for Experimental Biotech Drugs – New Opportunities and Risks for AI-Powered Drug Development

As MIT Technology Review reports (https://www.technologyreview.com/2026/07/30/1140942/montana-experimental-medical-hub-pushed-forward-right-to-try/), the U.S. state of Montana recently passed a groundbreaking regulation that allows biotechnology companies to sell experimental drugs directly to consumers after very short testing phases. This innovation also affects the growing number of drugs developed with the help of artificial intelligence (AI), which have so far often had to undergo lengthy approval processes.

New Approval Pathways for Experimental Drugs

Under the new regulation, companies whose drugs have already been tested in small studies with about ten healthy volunteers can apply for approval from a specially established review board. The fee for this application is $12,500. After a positive evaluation, the drug may be brought to market without having to complete the otherwise usual extensive clinical trials. This approach is part of Montana's initiative to establish itself as an "experimental medical hub" and accelerate access to innovative therapies. However, critics warn of risks to patient safety and the potential circumvention of established scientific standards.

Significance for AI-Powered Drug Development

The development of drugs using AI has gained enormous importance in recent years. Algorithms can analyze large amounts of data, identify drug candidates faster, and even enable personalized therapies. Nevertheless, extensive testing for safety and efficacy remains essential. Montana's new regulation could represent a significant competitive advantage for AI-powered biotech companies, as they can bring their products to market faster and more cost-effectively. This could increase the speed of innovation and provide patients with early access to novel therapies.

Risks and Ethical Questions

At the same time, the shortened approval process raises ethical and medical questions. The limited testing carries the risk of unexpected side effects or ineffective treatment. Patients face the danger of being used as guinea pigs without sufficient safety data. Moreover, the new pathway could increase pressure on other states and countries to introduce similar regulations, potentially leading to a patchwork of differing standards. The role of AI in this context is ambivalent: on the one hand, it can minimize risks; on the other hand, insufficiently tested AI models could make incorrect predictions.

Why It Matters

Montana's initiative shows how regulatory frameworks can significantly influence the development and dissemination of AI-powered drugs. For researchers, companies, and patients, this means new opportunities but also challenges in dealing with safety, transparency, and ethical responsibility. Montana's decision could serve as a test case for how innovation and regulation in medicine will interact in the future. Observers from politics and science should closely monitor the effects to ensure responsible handling of AI in drug development.